Physician profile
Lin H Chen
NPI 1285636654
$69,376.64
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,692 · 2020: $3,000 · 2021: $18K · 2022: $12K · 2023: $12K · 2024: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,255 · Travel and Lodging: $1,737 · Food and Beverage: $594 · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,081.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,255.00 |
| Travel and Lodging | $1,737.25 |
| Food and Beverage | $593.72 |
| Education | $507.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valneva USA, INC. | $26,501.09 | 2019-2024 | |
| Valneva Austria Gmbh | $18,200.00 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $10,965.07 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,100.00 | 2024 | |
| Bavarian Nordic A/S | $4,035.48 | 2024 | Encepur |
| Sanofi Pasteur INC. | $3,322.33 | 2021 | |
| Emergent Biosolutions INC. | $1,087.50 | 2021 | |
| Sirtex Medical INC | $117.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.33 | 2019 | |
| La Jolla Pharmaceutical Company | $18.96 | 2023 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.